These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29721733)

  • 41. Diagnostic yield of upper endoscopy in paediatric patients with Crohn's disease and ulcerative colitis. Subanalysis of the HUPIR registry.
    Kovacs M; Muller KE; Arato A; Lakatos PL; Kovacs JB; Varkonyi A; Solyom E; Polgar M; Nemes E; Guthy I; Tokodi I; Toth G; Horvath A; Tarnok A; Tomsits E; Csoszánszky N; Balogh M; Vass N; Bodi P; Dezsofi A; Gardos L; Micskey E; Papp M; Szucs D; Cseh A; Molnar K; Szabo D; Veres G;
    J Crohns Colitis; 2012 Feb; 6(1):86-94. PubMed ID: 22261532
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Different production of soluble HLA-G antigens by peripheral blood mononuclear cells in ulcerative colitis and Crohn's disease: a noninvasive diagnostic tool?
    Rizzo R; Melchiorri L; Simone L; Stignani M; Marzola A; Gullini S; Baricordi OR
    Inflamm Bowel Dis; 2008 Jan; 14(1):100-5. PubMed ID: 17886287
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Electric activity of the gut in ulcerative colitis and Crohn's disease: electromyography as a tool for differentiating between the two conditions in the early stage.
    Shafik A; Ahmed I; Shafik AA; El-Sibai O
    Med Sci Monit; 2004 Oct; 10(10):CR572-6. PubMed ID: 15448597
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
    Farkas K; Rutka M; Ferenci T; Nagy F; Bálint A; Bor R; Milassin Á; Fábián A; Szántó K; Végh Z; Kürti Z; Lakatos PL; Szepes Z; Molnár T
    Expert Opin Biol Ther; 2017 Nov; 17(11):1325-1332. PubMed ID: 28819991
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
    Colombel JF; Jharap B; Sandborn WJ; Feagan B; Peyrin-Biroulet L; Eichner SF; Robinson AM; Mostafa NM; Zhou Q; Thakkar RB
    Aliment Pharmacol Ther; 2017 Jan; 45(1):50-62. PubMed ID: 27883215
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Active and passive smoking behaviour and cessation plans of patients with Crohn's disease and ulcerative colitis.
    van der Heide F; Dijkstra A; Albersnagel FA; Kleibeuker JH; Dijkstra G
    J Crohns Colitis; 2010 Jun; 4(2):125-31. PubMed ID: 21122495
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study.
    Melmed GY; Elashoff R; Chen GC; Nastaskin I; Papadakis KA; Vasiliauskas EA; Liu W; Landers C; Ippoliti AF; Targan SR
    Clin Gastroenterol Hepatol; 2007 May; 5(5):602-8; quiz 525. PubMed ID: 17478347
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bonferroni-Holm and permutation tests to compare health data: methodological and applicative issues.
    Giacalone M; Agata Z; Cozzucoli PC; Alibrandi A
    BMC Med Res Methodol; 2018 Jul; 18(1):81. PubMed ID: 30029629
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peripheral cytokine profile in Chilean patients with Crohn's disease and ulcerative colitis.
    Beltrán CJ; Candia E; Erranz B; Figueroa C; Gonzalez MJ; Quera R; Hermoso MA
    Eur Cytokine Netw; 2009 Mar; 20(1):33-8. PubMed ID: 19318319
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Extraintestinal manifestations in Crohn's disease and ulcerative colitis: results from a prospective, population-based European inception cohort.
    Isene R; Bernklev T; Høie O; Munkholm P; Tsianos E; Stockbrügger R; Odes S; Palm Ø; Småstuen M; Moum B;
    Scand J Gastroenterol; 2015 Mar; 50(3):300-5. PubMed ID: 25535653
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systematic analysis of annual health resource utilization and costs in hospitalized patients with inflammatory bowel disease in Switzerland.
    Schoepfer A; Vavricka SR; Brüngger B; Reich O; Blozik E; Bähler C
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):868-875. PubMed ID: 29757772
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Untargeted Metabolomics and Inflammatory Markers Profiling in Children With Crohn's Disease and Ulcerative Colitis-A Preliminary Study.
    Daniluk U; Daniluk J; Kucharski R; Kowalczyk T; Pietrowska K; Samczuk P; Filimoniuk A; Kretowski A; Lebensztejn D; Ciborowski M
    Inflamm Bowel Dis; 2019 Jun; 25(7):1120-1128. PubMed ID: 30772902
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Ulcerative colitis and Crohn's disease. Modern views. Part 2. Diagnostics and differential therapy].
    Tsimmerman IaS; Tsimmerman IIa; Tret'iakova IuI
    Klin Med (Mosk); 2013; 91(12):9-16. PubMed ID: 25702423
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The incidence of ulcerative colitis (1995-2011) and Crohn's disease (1995-2012) - based on nationwide Danish registry data.
    Nørgård BM; Nielsen J; Fonager K; Kjeldsen J; Jacobsen BA; Qvist N
    J Crohns Colitis; 2014 Oct; 8(10):1274-80. PubMed ID: 24675473
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term evolution and predictive factors of mild inflammatory bowel disease.
    Reenaers C; Pirard C; Vankemseke C; Latour P; Belaiche J; Louis E
    Scand J Gastroenterol; 2016; 51(6):712-9. PubMed ID: 26815198
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Blood-based biomarkers used to predict disease activity in Crohn's disease and ulcerative colitis.
    Burakoff R; Pabby V; Onyewadume L; Odze R; Adackapara C; Wang W; Friedman S; Hamilton M; Korzenik J; Levine J; Makrauer F; Cheng C; Smith HC; Liew CC; Chao S
    Inflamm Bowel Dis; 2015 May; 21(5):1132-40. PubMed ID: 25895006
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The incidence of Crohn's disease and ulcerative colitis since 1995 in Danish children and adolescents <17 years - based on nationwide registry data.
    Larsen MD; Baldal ME; Nielsen RG; Nielsen J; Lund K; Nørgård BM
    Scand J Gastroenterol; 2016 Sep; 51(9):1100-5. PubMed ID: 27160395
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease.
    Rubin DT; Mody R; Davis KL; Wang CC
    Aliment Pharmacol Ther; 2014 May; 39(10):1143-55. PubMed ID: 24697826
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fistulizing pattern in Crohn's disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study.
    Biancone L; Zuzzi S; Ranieri M; Petruzziello C; Calabrese E; Onali S; Ascolani M; Zorzi F; Condino G; Iacobelli S; Pallone F
    J Crohns Colitis; 2012 Jun; 6(5):578-87. PubMed ID: 22398047
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inflammatory bowel disease in an underdeveloped region of Northeastern Brazil.
    Parente JM; Coy CS; Campelo V; Parente MP; Costa LA; da Silva RM; Stephan C; Zeitune JM
    World J Gastroenterol; 2015 Jan; 21(4):1197-206. PubMed ID: 25632193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.